ロイマ性疾患のAntistreptolysin價について
スポンサーリンク
概要
- 論文の詳細を見る
In 1932, it was reported by Dr. Todd & her co-workers that the streptolysin "O" produced from group A hemolytic streptococci had a common antigen throughout almost other pathogenic groups (C, G etc.). Since then, in foreign countries, antistreptolysin,'O" titer in patients' serum has been measured quantatively as a routine work for the purpose of diagnosis and prognosis in the diseases which caused from hemolytic streptococcal infection particularly in rheumatic diseases. I am regret that we have ever got no reports about antistreptolysintiter of rheumatic and other diseases tested by any clinical laboratory worker in Japan. Since January 1949, I have examined antistreptolysin test according to Dr. Todd's method about rheumatic diseases (22 cases), scarlet fever (16 cases) and other diseases (13 cases) with a course of disease. (See Table 1, 2, 3) And I found that almost rheumatic patients had maintained the high titer in this test throughout every stage of the illness not refering to the genesis of the disease. On the other hand, in the scarlet fever I could observe that most of patients were demonstrated having gradually rising titer with the course of disease. About the genesis of rheumatic fever, a great many discussions have been disputed for a long time and recently it is suggested that it may be polygenetic and we also agree with theory. From above results, however, I can not help recognizing the fact that almost rheumatic patients have ever had the anamnesis of hemolytic streptococcal infection before, even if the direct cause of the disease is not clear.
- 社団法人日本循環器学会の論文
- 1951-03-20
著者
関連論文
- 122)リウマチ性疾患の臨床的研究(第2報) : リウマチ性疾患の血清補體價に就て(第15回日本循環器學會)
- 5) ロイマ性疾患のAntistreptolysin價について(日本循環器學會第14回總會記事)
- ロイマ性疾患のAntistreptolysin價について